Related Experiment Video

Updated: Dec 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Corinne Maurice Dror1, Kim Nguyen Chi2

  • 1Division of Oncology, Rambam Health care Campus, Haifa, Israel.

Future Oncology (London, England)
|September 5, 2020
PubMed

Insights

Apalutamide improves survival for men with metastatic castration-sensitive prostate cancer (mCSPC). This next-generation androgen receptor inhibitor offers a survival benefit when added to standard therapy for advanced prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of cancer death in men, primarily due to metastatic disease.
  • Metastatic castration-sensitive prostate cancer (mCSPC) treatment benefits from docetaxel or androgen signaling inhibitors combined with androgen deprivation therapy.
  • Apalutamide, a novel androgen receptor inhibitor, has demonstrated survival benefits in mCSPC.

Purpose of the Study:

  • To review the preclinical activity and clinical efficacy of apalutamide.
  • To focus on apalutamide's efficacy in treating metastatic castration-sensitive prostate cancer (mCSPC).

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data on apalutamide in mCSPC.

Main Results:

  • Apalutamide has shown preclinical anti-cancer activity.
  • Clinical studies confirm apalutamide provides an added survival benefit in mCSPC.
  • Apalutamide is approved for mCSPC treatment based on survival data.

Conclusions:

  • Apalutamide is an effective treatment option for mCSPC.
  • The evidence supports apalutamide's role in improving survival for men with mCSPC.
Keywords:
TITAN trialadditional indicationsapalutamidecastrate sensitiveefficacyfuture trialsmechanism of actionmetastaticprostate cancertoxicity

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

472

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K